BWV BLUE WATER VACCINES INC

Blue Water Biotech Announces It Has Regained Compliance with Nasdaq Listing Rule 5250(c)(1)

Blue Water Biotech Announces It Has Regained Compliance with Nasdaq Listing Rule 5250(c)(1)

CINCINNATI, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. (Nasdaq: BWV) ("BWB" or the “Company”) today announced that it has received a letter from the Nasdaq Stock Market, LLC ("Nasdaq") stating that the Company has regained compliance with the Nasdaq Stock Market, LLC Listing Rule 5250(c)(1) (the "Rule").

The Rule requires listed companies to timely file all required periodic financial reports with the Securities and Exchange Commission (SEC). On October 20, 2023, BWB filed its Form 10-Q for the period ended June 30, 2023, and thus is now current on its SEC financial reporting obligations.

About Blue Water Biotech, Inc.

Blue Water Biotech, Inc. is a commercial stage biotechnology company focused on the research, development, and commercialization of innovative solutions for oncology. The Company currently has Entadfi®, an oral therapeutic for the treatment of benign prostatic hyperplasia (BPH), a disorder of the prostate, along with building additional assets in therapeutics, diagnostics, and clinician services for oncology.

Investor and Media Contact Information:

Russo Partners, LLC

Nic Johnson and Harrison Seidner, PhD

Telephone: (212) 845-4242

Email:



EN
01/11/2023

Underlying

BWVBLUE WATER VACCINES INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on BLUE WATER VACCINES INC

 PRESS RELEASE
Free
BWV BLUE WATER VACC...

Onconetix and Ocuvex Therapeutics announce execution of definitive mer...

Onconetix and Ocuvex Therapeutics announce execution of definitive merger agreement CINCINNATI, July 16, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc. (Nasdaq: ONCO) (“Onconetix” or the “Company”) and Ocuvex Therapeutics, Inc. (“Ocuvex”), a privately held biopharmaceutical company focused on the development and commercialization of ophthalmic therapeutic candidates, today announced that they have entered into a definitive merger agreement (the “Merger Agreement”). Andrew J. Oakley, Chairman of the Board of Onconetix, stated, “We continue to believe that the proposed transaction with Ocuvex, w...

July 16, 2025 1 EN
 PRESS RELEASE
Free
BWV BLUE WATER VACC...

Onconetix, Inc. Announces Positive Decision by Nasdaq Hearings Panel

Onconetix, Inc. Announces Positive Decision by Nasdaq Hearings Panel CINCINNATI, Ohio, June 16, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc. (Nasdaq: ONCO) (“Onconetix” or the “Company”), a commercial-stage biotechnology company focused on the research, development, and commercialization of innovative solutions for men’s health and oncology, today reported that on June 11, 2025, the Company received a decision from the Nasdaq Hearings Panel granting the Company’s request for continued listing on The Nasdaq Stock Market, subject to the Company demonstrating compliance with the Nasdaq Listing ...

June 16, 2025 1 EN
 PRESS RELEASE
Free
BWV BLUE WATER VACC...

Onconetix, Inc. Announces 1-for-85 Reverse Stock Split and Results of ...

Onconetix, Inc. Announces 1-for-85 Reverse Stock Split and Results of the Special Meeting of Stockholders CINCINNATI, Ohio, June 11, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc. (NASDAQ: ONCO) (“Onconetix” or the “Company”), a commercial-stage biotechnology company focused on the research, development, and commercialization of innovative solutions for men’s health and oncology, today announced that the Company’s stockholders have approved a proposal to effect a reverse split, which was voted on at the Company’s 2025 special meeting of stockholders (the “Special Meeting”) held on May 30, 202...

June 11, 2025 1 EN
 PRESS RELEASE
Free
BWV BLUE WATER VACC...

Onconetix, Inc. Announces Receipt of Additional Notice from Nasdaq

Onconetix, Inc. Announces Receipt of Additional Notice from Nasdaq Cincinnati, OH, May 22, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc. (Nasdaq: ONCO) (the “Company”) announced that it received a Staff delisting letter from The Nasdaq Capital Market (“Nasdaq”) on May 20, 2025 indicating that the Company’s failure to file its Quarterly Report on Form 10-Q for the three months ended March 31, 2025 (the “10-Q”) is in violation of Nasdaq’s continued listing requirements under Nasdaq Listing Rule 5250(c)(1) (the “Rule”). This announcement is made in compliance with Nasdaq Listing Rule 5810(b), w...

May 22, 2025 1 EN
 PRESS RELEASE
Free
BWV BLUE WATER VACC...

Onconetix, Inc. Announces Receipt of Additional Notice from Nasdaq

Onconetix, Inc. Announces Receipt of Additional Notice from Nasdaq Cincinnati, OH, April 30, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc. (Nasdaq: ONCO) (the “Company”) announced that it received a Staff delisting letter from The Nasdaq Capital Market (“Nasdaq”) on April 24, 2025 indicating that the Company’s failure to file its Annual Report on Form 10-K for the fiscal year ended December 30, 2024 is in violation of Nasdaq’s continued listing requirements under Nasdaq Listing Rule 5250(c)(1) (the “Rule”).   This announcement is made in compliance with Nasdaq Listing Rule 5810(b), which requ...

April 30, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch